AUDENTES THERAPEUTICS INC's ticker is BOLD and the CUSIP is 05070R104. A total of 149 filers reported holding AUDENTES THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is 0.35 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $78,346,000 | +65.2% | 1,309,250 | -22.5% | 0.01% | +25.0% |
| Q3 2019 | $47,433,000 | -32.5% | 1,688,616 | -9.0% | 0.00% | -20.0% |
| Q2 2019 | $70,262,000 | +30.0% | 1,855,826 | +34.0% | 0.01% | +25.0% |
| Q1 2019 | $54,060,000 | +55.4% | 1,385,442 | -15.1% | 0.00% | +33.3% |
| Q4 2018 | $34,794,000 | -31.4% | 1,631,971 | +27.5% | 0.00% | -25.0% |
| Q3 2018 | $50,694,000 | +1.3% | 1,280,443 | -2.2% | 0.00% | 0.0% |
| Q2 2018 | $50,036,000 | +67.4% | 1,309,504 | +31.6% | 0.00% | +33.3% |
| Q1 2018 | $29,893,000 | +66.7% | 994,770 | +73.3% | 0.00% | +200.0% |
| Q4 2017 | $17,937,000 | +153.7% | 573,961 | +127.5% | 0.00% | 0.0% |
| Q3 2017 | $7,070,000 | +67.0% | 252,284 | +14.0% | 0.00% | – |
| Q2 2017 | $4,234,000 | +272.4% | 221,276 | +231.6% | 0.00% | – |
| Q1 2017 | $1,137,000 | -1.2% | 66,732 | +6.0% | 0.00% | – |
| Q4 2016 | $1,151,000 | +82.1% | 62,980 | +77.4% | 0.00% | – |
| Q3 2016 | $632,000 | – | 35,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 1,806,832 | $50,862,321,000 | 38.71% |
| Casdin Capital, LLC | 400,000 | $11,204,000 | 3.16% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,525,410 | $42,727,000 | 1.92% |
| Opaleye Management Inc. | 180,000 | $5,041,000 | 1.78% |
| Redmile Group, LLC | 1,289,332 | $36,114,000 | 1.78% |
| Cormorant Asset Management, LP | 323,545 | $9,062,000 | 1.60% |
| Orbimed Advisors | 4,129,638 | $115,671,000 | 1.10% |
| Perceptive Advisors | 1,562,618 | $43,770,000 | 0.84% |
| Rock Springs Capital Management LP | 525,000 | $14,705,000 | 0.68% |
| SPHERA FUNDS MANAGEMENT LTD. | 95,000 | $2,661,000 | 0.38% |